The Current Ratio as of September 2024 (TTM) for InflaRx N.V. (IFRX) is 8.91

According to InflaRx N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 8.91. This represents a change of -1.63% compared to the average of 9.06 of the last 4 quarters.

InflaRx N.V. (IFRX) Historical Current Ratio (quarterly & annually)

How has IFRX Current Ratio performed in the past?

The mean historical Current Ratio of InflaRx N.V. over the last ten years is 11.92. The current 8.91 Current Ratio has changed 7.38% with respect to the historical average. Over the past ten years (40 quarters), IFRX's Current Ratio was at its highest in in the June 2018 quarter at 43.98. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

InflaRx N.V. (IFRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of InflaRx N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

InflaRx N.V. (IFRX) Average Current Ratio

How has IFRX Current Ratio performed in the past?

The current Current Ratio of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

InflaRx N.V. (IFRX) Current Ratio vs. Peers

How is IFRX’s Current Ratio compared to its peers?

InflaRx N.V.’s Current Ratio is greater than Generation Bio Co. (7.42), greater than Kronos Bio, Inc. (8.49), less than Erasca, Inc. (16.79), greater than C4 Therapeutics, Inc. (5.09), less than Edgewise Therapeutics, Inc. (30.24), less than Kezar Life Sciences, Inc. (9.58), less than Fulcrum Therapeutics, Inc. (22.07), greater than Passage Bio, Inc. (7.67), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Galera Therapeutics, Inc. (5.63), less than Inozyme Pharma, Inc. (9.84), less than Eledon Pharmaceuticals, Inc. (14.48), less than Icosavax, Inc. (18.06), less than Ocuphire Pharma, Inc. (10.68), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Protalix BioTherapeutics, Inc. (1.33), greater than EyePoint Pharmaceuticals, Inc. (4.75), greater than SELLAS Life Sciences Group, Inc. (1.02), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67),

Build a custom stock screener for InflaRx N.V. (IFRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

InflaRx N.V. (IFRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.